Clinical Trials Logo

Clinical Trial Summary

The primary aim of this randomized controlled trial is to evaluate the effect of ConquerFear-Group (CF-G), compared with a control condition (CC), on Fear of Cancer Recurrence (FCR). Secondary aims are to explore the effect of CF-G on emotion regulation and additional psychological outcomes, and to explore mediating effects of emotion regulation, metacognitions, working alliance, patient adherence, and group cohesion. In addition, treatment expectancy, participation in other treatments after completion of the intervention of the study and demographic and clinical variables will be explored as moderators.


Clinical Trial Description

A randomized controlled trial testing the efficacy of ConquerFear-Group (CF-G) on breast cancer survivors with clinical levels of Fear of Cancer Recurrence (FCR), compared with a control condition (CC), will be conducted. The aims are to: 1. Evaluate the efficacy of CF-G on FCR, 2. Explore the effects on the secondary outcomes of emotion regulation, general distress, health-related QoL, survivors' unmet needs, mindfulness, metacognitions, intervention satisfaction, negative effects of intervention, and sleep. 3. Explore emotion regulation, metacognitions, working alliance, patient adherence, and group cohesion will be explored as possible mediators.* 4. Explore treatment expectancy, participation in other treatments after completion of the CF-G or the CC and demographic and clinical variables as possible moderators. Primary hypothesis: CF-G will yield larger reductions in FCR than CC at post treatment, and the effect will be maintained through the follow-up period. Secondary hypotheses: CF-G will demonstrate a larger improvement in measures of emotion regulation than CC following the intervention period. Changes in emotion regulation during treatment will mediate the effect of CF-G on FCR.* Changes in metacognitions during treatment will mediate the effect of CF-G on FCR.* CF-G will yield larger reductions in general distress, health-related QoL, survivors' unmet needs than CC, and CF-G will yield larger improvements in metacognitions, mindfulness, and sleep than CC following the intervention period. *The prerequesties for conducting for mediation analysis were not fulfilled. Consequently, these analyses were abandoned. Data can be obtained upon request. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04137575
Study type Interventional
Source Aarhus University Hospital
Contact
Status Completed
Phase N/A
Start date October 21, 2019
Completion date June 22, 2022

See also
  Status Clinical Trial Phase
Completed NCT03080623 - Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
Completed NCT05527769 - Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
Completed NCT06376578 - Exercise Interventions for Improving Health in Breast Cancer Survivors N/A
Completed NCT03004534 - A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide Early Phase 1
Recruiting NCT05020574 - Microbiome and Association With Implant Infections Phase 2
Active, not recruiting NCT06277141 - The Vitality Mammography Messaging Study N/A
Completed NCT03270111 - High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women N/A
Completed NCT03555227 - USG PECS vs LIA for Breast Cancer Surgery N/A
Active, not recruiting NCT03917082 - Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer Phase 2
Recruiting NCT05561842 - Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
Completed NCT04554056 - Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF Phase 2/Phase 3
Active, not recruiting NCT03127995 - Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence N/A
Active, not recruiting NCT02237469 - Prone Breast Radiotherapy Treatment Planning Observational Study
Completed NCT01204125 - Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Phase 2
Recruiting NCT04565054 - Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC Phase 3
Not yet recruiting NCT06412133 - Conversations in Light and Shadow: Assessing Phototherapy's Impact on Breast Cancer Patients N/A
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Recruiting NCT06087120 - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting NCT06058936 - Exercises Using Virtual Reality on Cancer Patients N/A
Completed NCT03470935 - Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger